Patients were stratified into 4 risk groups based on recent heart failure hospitalization (HFH) and use of loop diuretics. 1 ...

Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients ...

The approval of lenacapavir for use as pre-exposure prophylaxis is a significant step in reducing the incidence of HIV across ...

Discontinuing the weight loss treatment before hitting the recommended maintenance dose contributes to low-value care despite ...

Surbhi Sidana, MD, MBBS, director of the Myeloma Disease Focused Group at Stanford University, provides a reintroduction to ...

Early trials found that both garadacimab and sebetralstat were safe when used in patients living with hereditary angioedema, ...

Making clinical trials easier to find for clinicians and making protocols for entering clinical trials more lenient can help ...

Panelists discuss how riociguat targets the nitric oxide pathway and is approved for both Group 1 PAH and Group 4 chronic ...

Panelists discuss how combination therapies targeting different aspects of spinal muscular atrophy (SMA), such as myostatin ...

Panelists discuss how insurance challenges impact spinal muscular atrophy (SMA) care, with prior authorizations becoming more ...

Median overall survival was 5 months longer in patients with small cell lung cancer (SCLC) who received tarlatamab instead of ...

Nemolizumab significantly and safely improved itch and skin lesions for up to 2 years in patients with moderate to severe prurigo nodularis.